Table 3 |
||||
|
Distribution of HPV16 and other most prevalent genotypes in CIN lesions and ICC |
||||
|
HPV genotypes |
ICC Total (%) n = 33 |
CIN2-3 Total (%) n = 14 |
CIN-1 Total (%) n = 12 |
Controls Total (%) n = 20 |
|
|
||||
|
HPV-16 only |
5 (15.1) |
1 (7.1) |
0 (0.0) |
1 (5.0) |
|
HPV16 with HPV-18 only |
5 (15.1) |
2 (14.2) |
0 (0.0) |
2 (10.0) |
|
HPV16 with HPV 18,35,45, or 31 |
20 (60.6) |
2 (14.2) |
1 (8.3) |
3 (15.0) |
|
HPV16 with HPV 18,31,33,35,45,52,58,68,82 |
30 (90.9) |
2 (14.2) |
1 (8.3) |
3 (15.0) |
|
HPV16 with HPV 6, 11,18,31,33,35,45,52,58,61,62,68,73,81,82 |
33 (100) |
3 (21.3) |
2 (16.6) |
4 (20.0) |
|
Other HR-HPV single infections 18,35,45,51,58,66 |
33 (100) |
4 (28.6) |
6 (50.0) |
8 (40.0) |
|
HPV 18,26,35,45,51,53,56,58,59,66, excluding HPV16 |
33 (100) |
13 (92.8) |
12 (100) |
18 (90.0) |
|
HPV 18,26,35,42,45,51,53,55,56,58,59,61,66,69,70,72,81,83,84, excluding HPV16 |
33 (100) |
14 (100) |
12 (100) |
20 (100) |
|
|
||||
|
Vidal et al. Infectious Agents and Cancer 2011 6:20 doi:10.1186/1750-9378-6-20 |
||||
